1. Home
  2. SKY vs ACAD Comparison

SKY vs ACAD Comparison

Compare SKY & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SKY

Skyline Champion Corporation

HOLD

Current Price

$84.32

Market Cap

4.3B

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$26.66

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKY
ACAD
Founded
2010
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3B
4.2B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
SKY
ACAD
Price
$84.32
$26.66
Analyst Decision
Buy
Buy
Analyst Count
2
21
Target Price
$85.00
$29.24
AVG Volume (30 Days)
717.0K
1.5M
Earning Date
11-04-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
48.48
98.53
EPS
3.84
1.54
Revenue
$2,624,539,000.00
$1,047,118,000.00
Revenue This Year
$5.10
$15.16
Revenue Next Year
$4.21
$11.42
P/E Ratio
$21.76
$17.26
Revenue Growth
12.14
12.69
52 Week Low
$59.44
$13.40
52 Week High
$116.49
$26.75

Technical Indicators

Market Signals
Indicator
SKY
ACAD
Relative Strength Index (RSI) 60.64 73.30
Support Level $75.94 $22.81
Resistance Level $87.17 $25.20
Average True Range (ATR) 2.83 0.86
MACD 0.17 0.25
Stochastic Oscillator 73.25 98.98

Price Performance

Historical Comparison
SKY
ACAD

About SKY Skyline Champion Corporation

Champion Homes Inc is a factory-built housing company in North America. The company is well positioned with an portfolio of manufactured and modular homes, ADUs, park-models and modular buildings for the single-family, multi-family, and other hospitality sectors. In addition to its core home building business, the company provides construction services to install and set-up factory-built homes, operates a factory-direct retail business with 72 retail locations across the United States, and operates Star Fleet Trucking, providing transportation services to the manufactured housing and other industries from several dispatch locations across the United States.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: